FDA Accepts Onyx’s Carfilzomib Application But Denies Priority Review
This article was originally published in The Pink Sheet Daily
“Our plan is to continue our dialogue with the FDA and see if we can address their concerns and get the accelerated approval done,” Onyx R&D chief Love told analysts. The company completed its application to treat patients with refractory and relapsed multiple myeloma in September based on results of a single-arm study, a design the agency may not be inclined to accept.
You may also be interested in...
Safety Concerns Weigh On Onyx’s Carfilzomib In Multiple Myeloma
In briefing documents released ahead of the Oncologic Drugs Advisory Committee’s June 20 review, FDA cites concerns about severe toxicities with the proteasome inhibitor and the limitations of a single-arm trial. With an overall response rate of “only” 22%, carfilzomib may not provide an advantage over available therapies in the relapsed/refractory setting, review documents state.
Deals Of The Week: Pfizer Goes For An IPO
Pfizer’s strategy is to monetize part of its animal health division while continuing new CEO Ian Read’s increased focus on biopharmaceuticals.
Deals of the Week: Watson/Actavis, Pfizer/Nestle, Celgene/Epizyme
With Bayer reportedly preparing to strike a multi-billion-dollar deal, investors are reacting by driving up the price of two different potential targets.